Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melphalan Flufenamide SCHEMBL18239898 | 0.92 | LMNA (0.53) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| Melphalan Flufenamide SCHEMBL24101233 | 0.92 | LMNA (0.53) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| Melphalan Flufenamide SCHEMBL20208719 | 0.92 | LMNA (0.53) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| Melphalan Flufenamide SCHEMBL29375249 | 0.92 | LMNA (0.52) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| SCHEMBL22240387 | 0.85 | LMNA (0.51) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| SCHEMBL25022336 | 0.85 | LMNA (0.43) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| SCHEMBL20208910 | 0.85 | LMNA (0.50) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| SCHEMBL10653540 | 0.84 | LMNA (0.47) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| SCHEMBL6838403 | 0.84 | LMNA (0.47) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A | |
| SCHEMBL24754637 | 0.84 | HDAC6 (0.49) | LMNASMN1; SMN2CYP3A4ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | ONCOPEPTIDES AB (SE) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | MME, SLC43A1, SLC7A5 | LMNA 3040/4885SMN1; SMN2 685/4885CYP3A4 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.